86 related articles for article (PubMed ID: 36870947)
1. Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study.
Zhang B; Song Y; Luo S; Yin X; Li E; Wang H; He Y; Liu Z; Fan Q; Liang X; Shu Y; Liu Y; Xu N; Zhang S; Zhuang Z; Zhang J; Kou X; Wang F; Zhu X; Zeng S; Wang K; Zhong H; Li S; Bai Y; Yu J; Dou Y; Ma T; Liu Q; Huang J
Cell Rep Med; 2023 Dec; 4(12):101301. PubMed ID: 38016482
[TBL] [Abstract][Full Text] [Related]
2. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Geurts BS; Zeverijn LJ; van Berge Henegouwen JM; van der Wijngaart H; Hoes LR; de Wit GF; Spiekman IA; Battaglia TW; van Beek DM; Roepman P; Jansen AM; de Leng WW; Broeks A; Labots M; van Herpen CM; Gelderblom H; Verheul HM; Snaebjornsson P; Voest EE
J Pathol; 2024 May; ():. PubMed ID: 38747304
[TBL] [Abstract][Full Text] [Related]
3. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol.
Geurts BS; Zeverijn LJ; Leek LVM; van Berge Henegouwen JM; Hoes LR; van der Wijngaart H; van der Noort V; van de Haar J; van Ommen-Nijhof A; Kok M; Roepman P; Jansen AML; de Leng WWJ; de Jonge MJA; Hoeben A; van Herpen CML; Westgeest HM; Wessels LFA; Verheul HMW; Gelderblom H; Voest EE
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38630551
[TBL] [Abstract][Full Text] [Related]
5. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).
Haj Mohammad SF; Timmer HJL; Zeverijn LJ; Geurts BS; Spiekman IAC; Verkerk K; Verbeek FAJ; Verheul HMW; Voest EE; Gelderblom H
Acta Oncol; 2024 May; 63():368-372. PubMed ID: 38779868
[TBL] [Abstract][Full Text] [Related]
6. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Zeverijn LJ; Looze EJ; Thavaneswaran S; van Berge Henegouwen JM; Simes RJ; Hoes LR; Sjoquist KM; van der Wijngaart H; Sebastian L; Geurts BS; Lee CK; de Wit GF; Espinoza D; Roepman P; Lin FP; Jansen AML; de Leng WWJ; van der Noort V; Leek LVM; de Vos FYFL; van Herpen CML; Gelderblom H; Verheul HMW; Thomas DM; Voest EE
Int J Cancer; 2023 Oct; 153(7):1413-1422. PubMed ID: 37424386
[TBL] [Abstract][Full Text] [Related]
7. Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review.
Wang R; Cong D; Bai Y; Zhang W
Front Pharmacol; 2023; 14():1207369. PubMed ID: 37448961
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.
Zheng Y; Shen G; Zhang C; Huo X; Xin Y; Fang Q; Guan Y; Zhao F; Ren D; Liu Z; Wang M; Zhao J
Clin Exp Med; 2023 Nov; 23(7):3205-3216. PubMed ID: 37120775
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review.
Mei WJ; Mi M; Qian J; Xiao N; Yuan Y; Ding PR
Front Immunol; 2022; 13():1019582. PubMed ID: 36618386
[TBL] [Abstract][Full Text] [Related]
10. Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review.
Li N; Wan Z; Lu D; Chen R; Ye X
Front Immunol; 2022; 13():1088683. PubMed ID: 36703977
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Geurts BS; Battaglia TW; van Berge Henegouwen JM; Zeverijn LJ; de Wit GF; Hoes LR; van der Wijngaart H; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Opdam FL; de Jonge MJA; Cirkel GA; Labots M; Hoeben A; Kerver ED; Bins AD; Erdkamp FGL; van Rooijen JM; Houtsma D; Hendriks MP; de Groot JB; Verheul HMW; Gelderblom H; Voest EE
BMC Cancer; 2023 Mar; 23(1):205. PubMed ID: 36870947
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
Oh CR; Kim JE; Hong YS; Kim SY; Ahn JB; Baek JY; Lee MA; Kang MJ; Cho SH; Beom SH; Kim TW
Int J Cancer; 2022 Jun; 150(12):2038-2045. PubMed ID: 35179785
[TBL] [Abstract][Full Text] [Related]
13. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A
Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
